Oncology Biosimilars Market

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

Oncology Biosimilars Market contains market size and forecasts of Oncology Biosimilars in global, including the following market information:

• Global Oncology Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Oncology Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Oncology Biosimilars companies in 2021 (%)

The global Oncology Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Oncology Biosimilars include Celltrion, Biocon, Dr. Reddy?s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Oncology Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oncology Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Oncology Biosimilars Market Segment Percentages, by Type, 2021 (%)

• Monoclonal Antibody
• Hematopoietic Agents
• G-CSF
• Others

Global Oncology Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Oncology Biosimilars Market Segment Percentages, by Application, 2021 (%)

• Retail Pharmacies
• Hospital Pharmacy
• Online Pharmacy

Global Oncology Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Oncology Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Oncology Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Oncology Biosimilars revenues share in global market, 2021 (%)
• Key companies Oncology Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Oncology Biosimilars sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Celltrion
• Biocon
• Dr. Reddy?s Laboratories
• STADA Arzneimittel AG
• Intas Pharmaceuticals
• Pfizer
• Sandoz International
• Teva Pharmaceutical Industries Ltd
• Apotex
• BIOCAD